EVP, Chief Development Officer Peterson Amy C. sale 7,463 shares of CytomX Therapeutics Inc. [CTMX]

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. CytomX Therapeutics Inc. shares valued at $10,612 were sold by Peterson Amy C. on Jul 20. At $1.42 per share, Peterson Amy C. sold 7,463 shares. The insider’s holdings dropped to 62,690 shares worth approximately $0.1 million following the completion of this transaction.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Also, Landau Jeffrey B sold 4,206 shares, netting a total of over 5,982 in proceeds. Following the sale of shares at $1.42 each, the insider now holds 30,725 shares.

Before that, ROWLAND LLOYD A had sold 5,602 shares from its account. In a trade valued at $7,968, the General Counsel traded CytomX Therapeutics Inc. shares for $1.42 each. Upon closing the transaction, the insider’s holdings decreased to 5,602 shares, worth approximately $71213.06999999999.

As published in a research note from Wedbush on July 07, 2022, CytomX Therapeutics Inc. [CTMX] has been rated down from an Outperform to a Neutral and the price target has been revised to $2 from $6. This represents a 18.5% premium over Thursday’s closing price. Analysts at Piper Sandler downgraded the stock from ‘”an Overweight”‘ to ‘”a Neutral”‘ outlook in a report released in early July. As of July 07, 2022, Mizuho has decreased its “Buy” rating to a “Neutral” for CTMX. Earlier on July 07, 2022, Jefferies downgraded its rating. Their new recommendation was “a Hold” for CTMX stock which previously was a “a Buy”.

Analyzing CTMX’s Price Performance

On Thursday, CytomX Therapeutics Inc. [NASDAQ: CTMX] rose 3.82% to $1.63. The stock’s lowest price that day was $1.57, but it reached a high of $1.64 in the same session. During the last five days, there has been a surge of approximately 13.99%. Over the course of the year, CytomX Therapeutics Inc. shares have dropped approximately -62.36%. Shares of the company reached a 52-week high of $4.7300 on 02/09/22 and a 52-week low of $1.1900 on 07/07/22. A 50-day SMA is recorded $1.6212, while a 200-day SMA reached $3.5359. Nevertheless, trading volume fell to 1.06 million shares from 1.4 million shares the previous day.

Support And Resistance Levels for CytomX Therapeutics Inc. (CTMX)

According to the 24-hour chart, there is a support level at 1.5867, which, if violated, would cause prices to drop to 1.5433. In the upper region, resistance lies at 1.6567. The next price resistance is at 1.6833. RSI (Relative Strength Index) is 56.16 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.1079, which suggests the price will decrease in the coming days. Percent R is at 3.57%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.

Is CytomX Therapeutics Inc. subject to short interest?

Stocks of CytomX Therapeutics Inc. saw a sharp steep in short interest on Jul 14, 2022 dropping by -2.35 million shares to 1.3 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 3.65 million shares. A decline of -180.77% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 0.36 of the overall float, the days-to-cover ratio (short ratio) decline to 0.36.

Which companies own the most shares of CytomX Therapeutics Inc. (CTMX)?

According to BVF Partners LP filings, the company currently owns 5,803,700 shares, which is about 8.87% of the total CTMX shares outstanding. The investor’s shares have plunged by 0 from its previous 13-F filing of 5803700.0 shares. With the completion of the sale transaction, RTW Investments LP’s stake is now worth $10,576,851. The Vanguard Group, Inc. acquire a 2.47% interest valued at $9.35 million while BlackRock Fund Advisors purchased a 60,579 stake. A total of -1,931,725 shares of CytomX Therapeutics Inc. were bought by Point72 Asset Management LP during the quarter, and 3,470,900 by Tang Capital Management LLC. In its current portfolio, Rubric Capital Management LP holds 2,406,449 shares valued at $4.4 million.

In terms of CytomX Therapeutics Inc. share price expectations, FactSet research, analysts set an average price target of $4.74 in the next 12 months, up nearly 122.93% from the previous closing price of $1.57. Analysts anticipate CytomX Therapeutics Inc. stock to reach $11.00 by 2022, with the lowest price target being $1.50. In spite of this, 10 analysts ranked CytomX Therapeutics Inc. stock as an Overweight at the end of 2022. On June 24, 2022, BMO Capital Markets assigned a price target of “an Outperform” to the stock and initiated coverage with a $9.

LEAVE A REPLY

Please enter your comment!
Please enter your name here